Clinical trials
Completed Phase 2 Hematologic Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 64 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 8 |
| Seagen Inc. | 8 |
| M.D. Anderson Cancer Center | 5 |
| Medical College of Wisconsin | 3 |
| National Center for Research Resources (NCRR) | 3 |
| Novartis Pharmaceuticals | 3 |
| Emory University | 2 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
| Apellis Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Diseases | 64 |
| Leukemia | 14 |
| Myelodysplastic Syndromes | 11 |
| Rare Diseases | 10 |
| Leukemia, Myeloid, Acute | 8 |
| Multiple Myeloma | 8 |
| Anemia | 7 |
| Anemia, Sickle Cell | 7 |
| Lymphoma, Non-Hodgkin | 7 |
| Neoplasms | 7 |
Trials
Showing 1 to 25 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.